Updates are available Correction dated 2022-03-03
Click to view Correction: https://doi.org/10.1007/s00417-022-05614-9
-
Authors
Kiessling, D.
Rennings, C.
Hild, M.
Lappas, A.
Dietlein, T.S.
Roessler, G.F.
Widder, R.A. http://orcid.org/0000-0001-7487-1501
-
Funding
Funding for this research was provided by:
Universitätsklinikum Köln
- License Information
-
More Information
Article History
Received: 13 October 2021
Revised: 10 December 2021
Accepted: 14 January 2022
First Online: 3 February 2022
Change Date: 3 March 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00417-022-05614-9
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board as well as the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The Institutional Review Board (Ethik und Kommission Klinische Studien, Dernbacher Gruppe Katharina Kasper, Germany) approved the study.
: David Kiessling: none; Corinna Rennings: none; Matthias Hild: none; Alexandra Lappas: none; Gernot F. Roessler: none; Randolf A. Widder: none; Thomas S. Dietlein: Santen Pharmaceutical Osaka Japan, Alcon Fort Worth USA. Stock interest: Bayer Leverkusen Germany, Johnson and Johnson New Brunswick, NJ. Lectures: Thea Pharma Schaffhausen Switzerland, iStar Medical Wawre Belgium, MeyeTech Alsdorf, Germany.
